Zabotina T N, Korotkova O V, Chertkova A I, Zakharova E N, Tabakov D V, Dzhgamadze N T, Savostikova M V, Artamonova E V, Khailenko V A, Kovalenko E I, Kadagidze Z G
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2018 Dec;166(2):241-244. doi: 10.1007/s10517-018-4323-3. Epub 2018 Nov 28.
In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16 lymphocytes and a negative correlation of this parameter with the number of regulatory CD4CD25CD127 cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8 and CD16) and elevated content of regulatory CD8CD11bCD28 T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8 T cell in comparison with ER breast cancer. The percentage of CD8 lymphocytes (CD3CD8 and CD8CD11bCD28) among lymphocytes infiltrating the tumor was higher in PR breast cancer than in PR tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.
在原发性可切除乳腺癌患者中，发现年龄与CD16淋巴细胞计数呈正相关，该参数与调节性CD4CD25CD127细胞数量及Ki-67肿瘤细胞增殖活性呈负相关。Ki-67水平较高与效应淋巴细胞（CD8和CD16）数量减少及调节性CD8CD11bCD28 T细胞含量升高有关。与雌激素受体阳性乳腺癌相比，雌激素受体表达缺失与CD8 T细胞细胞毒性潜能降低有关。孕激素受体阳性乳腺癌中浸润肿瘤的淋巴细胞中CD8淋巴细胞（CD3CD8和CD8CD11bCD28）的百分比高于孕激素受体阴性肿瘤。随着肿瘤负荷增加，表达CD16标志物的淋巴细胞数量及其细胞毒性潜能降低。
